| |
| |
This activity is supported by educational grants from
Amgen, Inc.
Celgene Corporation
Cephalon Oncology
Eisai Inc.
Lilly USA, LLC
Genentech BioOncology / Biogen Idec
Genzyme Corporation
Millennium Pharmaceuticals, Inc.
Novartis
sanofi-aventis Group |
| |
|
| |
1) Disclosure information available prior to the event
2) Available slides have been authorized for your reference by the presenter. |
|
| |
Chair
Ruemu E. Birhiray, MD
Hematology-Oncology of Indiana
Indianapolis, Indiana
bio | disclosures
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
bio | disclosures | slides
James O. Armitage, MD
University of Nebraska Medical Center
Omaha, Nebraska
bio | disclosures | slides
Richard W. Childs, MD, CMDR, USPHS
Bethesda, Maryland
bio | disclosures | slides
Neil E. Kay, MD
Mayo Clinic College of Medicine
Rochester, Minnesota
bio | disclosures | slides
Craig M. Kessler, MD
Georgetown University Medical Center
Washington, District of Columbia
bio | disclosures | slides
Larry W. Kwak, MD, PhD
MD Anderson Cancer Center
Houston, Texas
bio | disclosures | slides |
|
| |
Co-Chair
Michael C. Wiemann, MD
Providence Hospital/St. John Health
Warren, Michigan
bio | disclosures
Richard A. Larson, MD
University of Chicago
Chicago, Illinois
bio | disclosures | slides
David G. Maloney, MD, PhD
University of Washington
Seattle, Washington
bio | disclosures | slides
Richard M. Stone, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
bio | disclosures | slides
Martin S. Tallman, MD
Northwestern University Medical Center
Chicago, Illinois
bio | disclosures | slides
Ayalew Tefferi, MD
Mayo Clinic
Rochester, Minnesota
bio | disclosures | slides
|
|
|
 |
